Literature DB >> 2126693

In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa.

C I Bustamante1, R C Wharton, J C Wade.   

Abstract

The combinations of ciprofloxacin plus ceftazidime, ciprofloxacin plus aztreonam, and ciprofloxacin plus azlocillin were evaluated for the presence of synergy against multiresistant isolates of Pseudomonas aeruginosa. The frequency of synergy was dependent on antibiotic susceptibilities. If the organism was resistant to ciprofloxacin, synergy was observed in more than 50% of the isolates; however, if the organism was resistant to the beta-lactam (with the exception of ceftazidime), synergy was generally observed in less than 10% of the isolates. Antagonism was not observed with any of the combinations. These results may be helpful in making clinical decisions in treating P. aeruginosa infections.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2126693      PMCID: PMC171935          DOI: 10.1128/AAC.34.9.1814

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Ciprofloxacin interactions with imipenem and amikacin against multiresistant Pseudomonas aeruginosa.

Authors:  H Giamarellou; G Petrikkos
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

2.  Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens.

Authors:  C I Bustamante; G L Drusano; R C Wharton; J C Wade
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

Review 3.  Synergy of fluoroquinolones with other antimicrobial agents.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

4.  Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods.

Authors:  J A Moody; D N Gerding; L R Peterson
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

5.  Synergy of imipenem--a novel carbapenem, and rifampin and ciprofloxacin against Pseudomonas aeruginosa, Serratia marcescens and Enterobacter species.

Authors:  N X Chin; H C Neu
Journal:  Chemotherapy       Date:  1987       Impact factor: 2.544

6.  In-vitro study of the activity of ciprofloxacin alone and in combination against strains of Pseudomonas aeruginosa with multiple antibiotic resistance.

Authors:  G S Davies; J Cohen
Journal:  J Antimicrob Chemother       Date:  1985-12       Impact factor: 5.790

7.  Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.

Authors:  L J Chalkley; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

  7 in total
  7 in total

1.  Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

Authors:  J W Mouton; M L van Ogtrop; D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  High therapeutic index of factor C Sushi peptides: potent antimicrobials against Pseudomonas aeruginosa.

Authors:  Y H Yau; B Ho; N S Tan; M L Ng; J L Ding
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 3.  Combination therapy for treatment of infections with gram-negative bacteria.

Authors:  Pranita D Tamma; Sara E Cosgrove; Lisa L Maragakis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

4.  In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.

Authors:  George A Pankey; Deborah S Ashcraft
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

5.  Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.

Authors:  M E Klepser; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

6.  Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa.

Authors:  E B Jakics; S Iyobe; K Hirai; H Fukuda; H Hashimoto
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 7.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.